


SB1064 Transition Plan

January 17, 2012
Agenda Item #7

SB 1064

125290.71. Under the guidance of the ICOC, the institute shall, by January 31, 2012, create a transition plan addressing the expiration of current bond funding. A copy of the transition plan shall be transmitted to the Governor, the Controller, and the Legislature within 30 days of its completion.




Transition Plan Goal

Establish a platform to enable grantees, industry, other government agencies, disease foundations, venture capitalists and others to continue to pursue CIRM's mission upon the expiration of CIRM's bond funding.



CIRM's bond funding is limited to \$3 billion. Although additional funding could be a possibility in the future, it would be premature even to consider another bond measure at this time. Instead, CIRM should focus its efforts on creating a platform that enables others to carry on CIRM's work.

Through its funding of state of the art research facilities, collaborative funding agreements, and industry engagement, CIRM has already made progress in creating this platform.



Transition Plan Activities

- CIRM will explore and facilitate the creation of Alpha Stem Cell Clinics for the delivery of stem cell based therapies to patients and will work with its collaborative funding partners to replicate the model nationally and internationally.
- CIRM will continue to pursue and strengthen its joint funding efforts with state and international partners, the NIH, disease foundations, industry and venture capitalists in order to build relationships and promote follow-on funding for CIRM's research projects.
- CIRM will work to bring new biotechnology companies to California and create stem cell clusters to promote collaborations with California researchers and to provide a vehicle to translate stem cell discoveries into clinical applications.



Transition Plan Activities #2

- CIRM will explore the creation of a nonprofit venture philanthropy fund to provide funding for stem cell research projects, from IND-enabling research through Phase 2 trials.
- CIRM will fund the creation of an iPSC bank as a resource for California researchers and companies interested in disease modeling and drug discovery.
- CIRM will provide regulatory and product development guidance to its grantees to ensure that they have the tools necessary to take their discoveries from the bench to the bedside.
- CIRM will support efforts by its grantees to protect CIRM-funded intellectual property in order to safeguard the state's investment and promote the commercialization of CIRM-funded therapies.

